natgillin/translations-raw huggingface dataset:
In adults the results showed no significant difference in the pharmacokinetics of bevacizumab in relation to age. 
Rezultati so pokazali, da pri odraslih ni značilnih razlik v farmakokinetiki bevacuzimaba glede na starost.
• bleeding, including bleeding in the lungs in patients with non-small cell lung cancer, 
• krvavitev, vključno s krvavitvijo v pljučih pri bolnikih z nedrobnoceličnim rakom pljuč,
• dry skin, flaking and inflammation of the skin, change in skin colour, 
• suho kožo, luskavost in vnetje kože, spremembo barve kože,
• Redness of the eye, small particles or spots in your vision (floaters), eye pain, 
• pordelost očesa, majhni delci ali madeži v vidnem polju (motnjave), bolečina v očesu,
IFN alfa-2a was given up to 52 weeks or until disease progression at a recommended starting dose of 9 MIU three times a week, allowing a dose reduction to 3 MIU three times a week in 2 steps. 
Interferon alfa-2a so prejemali do 52 tednov ali do napredovanja bolezni, priporočeni začetni odmerek je bil 9 mio i.e. trikrat na teden, dovoljeno pa ga je bilo zmanjšati v dveh korakih na 3 mio i.e. trikrat na teden.
You must not use this medicine if you are pregnant. 
Če ste noseči, tega zdravila ne smete prejemati.
The concentrate is a clear to slightly opalescent, colourless to slightly yellow liquid in a glass vial with a rubber stopper. 
Koncentrat je bistro do rahlo opalescentna, brezbarvna do rahlo rumena tekočina v stekleni viali z gumijastim zamaškom.
Patients should be monitored for signs and symptoms of CNS bleeding, and MVASI treatment discontinued in cases of intracranial bleeding. 
Bolnike je treba spremljati za znake ali simptome krvavitev v osrednjem živčevju in zdravljenje z zdravilom MVASI v primerih intrakranialne krvavitve prekiniti.
If you stop treatment with MVASI 
Če ste prenehali jemati zdravilo MVASI
5 mg/kg IV 30-90 min Day 1, prior to FOLFOX-4, every 2 weeks 
30-90 min 1. dan, pred FOLFOX-4, vsaka 2 tedna
Trial results show that 94% (277 / 296) of eligible patients went on to receive single agent bevacizumab at cycle 7. 
Rezultati preskušanja kažejo, da je 94 % (277/296) primernih bolnikov s 7. ciklom nadaljevalo s samostojnim zdravljenjem z bevacizumabom.
Overall approximately 34% of patients were FIGO stage III optimally debulked with gross residual disease, 40% stage III suboptimally debulked, and 26% were stage IV patients. 
Celokupno je približno 34 % bolnic imelo po FIGO klasifikaciji bolezen stadija III, z opravljeno optimalno citoredukcijo, s preostankom bolezni; 40 % jih je imelo bolezen stadija III, z opravljeno suboptimalno citoredukcijo in 26 % je imelo bolezen stadija IV.
In the majority of the occasions the necessary amount of MVASI can be diluted with 0.9% sodium chloride solution for injection to a total volume of 100 mL. 
V večini primerov lahko potrebno količino zdravila MVASI razredčimo z 0,9-% raztopino natrijevega klorida za injiciranje do končnega volumna 100 ml.
The pharmacokinetics of bevacizumab were evaluated in 152 children, adolescents and young adults (7 months to 21 years, 5.9 to 125 kg) across 4 clinical studies in paediatrics using a population pharmacokinetic model. 
Farmakokinetiko bevacizumaba so ocenili pri 152 otrocih, mladostnikih in mlajših odraslih (7 mesecev do 21 let; 5,9 do 125 kg) v 4 kliničnih študijah pri pediatrični populaciji z uporabo populacijskega farmakokinetičnega modela.
Statistically significant improvements in progression-free survival and objective response rate were also observed (see table 8). 
Opazili so tudi statistično značilna izboljšanja v preživetju brez napredovanja bolezni in objektivnem odgovoru na zdravljenje (glejte preglednico 8).
Bevacizumab use has been associated with serious cases of fistulae including reactions resulting in death. 
Uporaba bevacizumaba je bila povezana z resnimi primeri fistul, vključno s takimi, ki so se končali s smrtjo.
• MVASI can increase the incidence of high blood pressure. 
• zdravilo MVASI lahko poveča pojavnost visokega krvnega tlaka.
The efficacy results of bevacizumab in combination with IFL-chemotherapy are displayed in table 4. 
Rezultate učinkovitosti bevacizumaba v kombinaciji z IFL-kemoterapijo prikazuje preglednica 4.
• fistula: abnormal tube-like connection between internal organs and skin or other tissues that are not normally connected, including connections between vagina and the gut in patients with cervical cancer. 
• fistule: nenormalne cevaste povezave med notranjimi organi in kožo ali drugimi tkivi, ki normalno niso povezani, med drugim povezave med nožnico in črevesom pri bolnicah z rakom materničnega vratu.
MVASI is also used for the treatment of adult patients with advanced non-small cell lung cancer when cancer cells have specific mutations of a protein called epidermal growth factor receptor (EGFR). 
Zdravilo MVASI uporabljamo tudi za zdravljenje odraslih bolnikov z napredovalim nedrobnoceličnim rakom pljuč, ko imajo rakave celice določene mutacije beljakovine, ki se imenuje receptor epidermalnega rastnega faktorja (EGFR).
Secondary PFS analyses, based on ‘on-treatment'-based response assessments, confirmed the significantly superior clinical benefit for patients treated with bevacizumab (analyses shown in table 7), consistent with the statistically significant benefit observed in the pooled analysis. 
Sekundarne analize preživetja brez napredovanja bolezni, ki so temeljile na ocenah odgovora ob zdravljenju (′on-treatment′), so potrdile signifikantno superiorno klinično korist za bolnike, ki so jih zdravili z bevacizumabom (analiza prikazana v preglednici 7), kar je v skladu s statistično signifikantno koristjo, ki so jo opazili v združenih analizah podatkov.
Overall survival6 
Celokupno preživetje6
• localised pus collection, 
• lokalizirano nabiranje gnoja,
In most clinical trials urine protein levels of ≥ 2g/24 hrs led to stopping treatment with bevacizumab until recovery to < 2g/24 hrs. 
V večini kliničnih preskušanj so koncentracije beljakovin v seču ≥ 2 g/24 ur povzročile prekinitev zdravljenja z bevacizumabom, dokler ni prišlo do zmanjšanja < 2 g/24 ur.
Bevacizumab 10 mg/kg was given every 2 weeks until disease progression. 
Bevacizumab so prejemali v odmerku 10 mg/kg vsaka dva tedna do napredovanja bolezni.
Most patients were FIGO stage IIIC or stage IV. 
Večina bolnic je imela stadij IIIC ali IV po klasifikaciji FIGO.
Efficacy results for study ML18147 (ITT population) 
Rezultati učinkovitosti za študijo ML18147 (populacija bolnikov, ki so jo nameravali zdraviti)
Efficacy results for trial BO17705 
Rezultati učinkovitosti preskušanja BO17705
Fistulae have also been reported in post-marketing experience. 
O fistulah so poročali tudi v obdobju po prihodu zdravila na trg.
If not used immediately, in-use storage times and conditions are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless dilution has taken place in controlled and validated aseptic conditions. 
Hranjenje navadno ne sme biti daljše od 24 ur pri temperaturi 2 °C do 8°C, razen če je bila raztopina pripravljena v kontroliranih in validiranih aseptičnih pogojih.
The efficacy data from trials AVF0780g and AVF2192g investigating bevacizumab in combination with 5-FU/FA chemotherapy are summarised in table 5. 
Podatki o učinkovitosti iz preskušanj AVF0780g in AVF2192g, ki sta proučevali bevacizumab v kombinaciji s kemoterapevtsko shemo 5-FU/FA, so povzeti v preglednici 5.
• increase in heart rate (pulse), 
• povišanje frekvence bitja srca (utripa),
Caution should be taken when treating these patients with MVASI. 
Pri zdravljenju teh bolnikov z zdravilom MVASI je zato potrebna previdnost.
The necessary amount of bevacizumab should be withdrawn and diluted to the required administration volume with sodium chloride 9 mg/mL (0.9%) solution for injection. 
Potrebno količino bevacizumaba je potrebno odvzeti in jo razredčiti do ustreznega volumna za aplikacijo z 9 mg/ml (0,9-%) raztopino natrijevega klorida za injiciranje.
These therapies in combination with MVASI may increase the risk of severe side effects. 
Ta zdravila lahko v kombinaciji z zdravilom MVASI povečajo tveganje za pojav hudih neželenih učinkov.
Do not use MVASI if you notice any particulate matter or discolouration prior to administration. 
Ne uporabljajte zdravila MVASI, če opazite kakršne koli delce ali obarvanje pred dajanjem.
• shortness of breath or low levels of oxygen in the blood, 
• zasoplost ali nizko vsebnost kisika v krvi,
• It is possible that MVASI may cause bleeding in and around your brain. 
• možno je, da lahko zdravilo MVASI povzroči krvavitve v možganih in okoli možganov.
The primary endpoint was PFS based on investigator's assessment of disease progression based on radiological scans or CA-125 levels, or symptomatic deterioration per protocol. 
Primarni cilj študije je bil preživetje brez napredovanja bolezni, ki temelji na oceni raziskovalca o napredovanju bolezni glede na radiološki posnetek ali določitvi vrednosti CA 125 oziroma na simptomatsko poslabšanje glede na protokol.
Studies in animals have shown reproductive toxicity including malformations (see section 5.3). 
Študije na živalih so pokazale škodljiv vpliv na sposobnost razmnoževanja, vključno z malformacijami (glejte poglavje 5.3).
• Pregnancy (see section 4.6). 
• Nosečnost (glejte poglavje 4.6).
A high proportion of patients (approximately 63% IFN/placebo; 55% bevacizumab/IFN) received a variety of non-specified post-trial anti-cancer therapies, including antineoplastic agents, which may have impacted the analysis of overall survival. 
Visok delež bolnikov (približno 63 % interferon/placebo; 55 % bevacizumab/placebo) je po zaključku študije prejemal različna nespecificirana zdravljenja novotvorb, vključno z antineoplastičnimi zdravili, kar je lahko imelo vpliv na analizo celokupnega preživetja.
Efficacy results from study AVF4095g 
Rezultati učinkovitosti iz študije AVF4095g
Hazard ratio was estimated from Cox proportional hazards models stratified by the duration of platinum free-interval prior to enrolling onto this study per eCRF (electronic case report form) and secondary surgical debulking status Yes/No (Yes = randomised to undergo cytoreduction or randomised to not undergo cytoreduction; No = not a candidate or did not consent to cytoreduction). 
Razmerje ogroženosti so ocenili iz Coxovih modelov sorazmernih ogroženosti, stratificiranih s trajanjem intervala brez platine pred vključitvijo v to študijo glede na elektronski obrazec za poročanje o primerih (eCRF, electronic case report form) in sekundarno s statusom kirurške odstranitve Da/Ne (Da = randomizirane, da bodo imele citoredukcijo ali randomizirane, da citoredukcije ne bodo imele; Ne = ni bila kandidatka za citoredukcijo ali z njo ni soglašala).
The pharmacokinetics of bevacizumab was well characterised by the paediatric population PK model for 70 paediatric patients in study BO20924 (1.4 to 17.6 years; 11.6 to 77.5 kg) and 59 patients in study BO25041 (1 to 17 years; 11.2 to 82.3 kg). 
Farmakokinetika bevacizumaba je bila dobro opredeljena z uporabo farmakokinetičnega modela pediatrične populacije za 70 pediatričnih bolnikov iz študije BO20924 (1,4 do 17,6 let; 11,6 do 77,5 kg) in za 59 bolnikov iz študije BO25041 (1 do 17 let; 11,2 do 82,3 kg).
• reduced blood supply to the brain or stroke, 
• zmanjšan dotok krvi v možgane ali kap,
In most clinical trials of bevacizumab, patients with pre-existing CHF of NYHA (New York Heart Association) II-IV were excluded, therefore, no information is available on the risk of CHF in this population. 
V večino kliničnih preskušanj z bevacizumabom bolniki, ki so imeli kongestivno srčno popuščanje pred pričetkom zdravljenja (NYHA - New York Heart Association II−IV), niso bili vključeni, zato informacije o tveganju za kongestivno srčno popuščanje pri tej populaciji niso na voljo.
In Part II, treatment assignment was double-blind with respect to bevacizumab. 
delu je bila določitev zdravljenja glede uporabe bevacizumaba dvojno slepa.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of concentrate contains 25 mg of bevacizumab*. 
KAKOVOSTNA IN KOLIČINSKA SESTAVA En ml koncentrata vsebuje 25 mg bevacizumaba*.
In clinical trials of metastatic carcinoma of the colon or rectum, there was no increased risk of postoperative bleeding or wound healing complications observed in patients who underwent major surgery 28-60 days prior to starting bevacizumab. 
V kliničnih preskušanjih metastatskega raka debelega črevesa in danke ni bilo povečanega tveganja za pooperativno krvavitev ali zaplete pri celjenju ran pri bolnikih, ki so imeli večjo operacijo 28 do 60 dni pred začetkom zdravljenja z bevacizumabom.
Infections and infestations Necrotising fasciitis, usually secondary to wound healing complications, gastrointestinal perforation or fistula formation (rare) (see also section 4.4) 
Infekcijske in parazitske bolezni nekrotizirajoči fasciitis, ponavadi sekundaren zapletom pri celjenju ran, perforaciji prebavil ali nastanku fistule (redko) (glejte tudi poglavje 4.4)
Combination with platinum- or taxane-based therapies (see sections 4.4 and 4.8) 
Kombinacija z zdravljenjem na osnovi platine ali taksanov (glejte poglavji 4.4 in 4.8)
The concentration of the final bevacizumab solution should be kept within the range of 1.4 mg/mL to 16.5 mg/mL. 
Koncentracija končne raztopine bevacizumaba mora biti od 1,4 do 16,5 mg/ml.
Overall survival3 
Celokupno preživetje3
• serious infections of the skin or deeper layers under the skin, especially if you had holes in the gut wall or problems with wound healing, 
• resne okužbe kože ali globljih plasti pod kožo, še posebno, če ste imeli luknje v črevesni steni ali težave pri celjenju ran,
Combination of bevacizumab and sunitinib malate 
Kombinacija bevacizumaba in sunitinibijevega malata
Patients with non-small cell lung cancer treated with bevacizumab may be at risk of serious, and in some cases fatal, pulmonary haemorrhage/haemoptysis. 
Pri bolnikih z nedrobnoceličnim rakom pljuč, ki se zdravijo z bevacizumabom, lahko obstaja tveganje za resno in v nekaterih primerih smrtno krvavitev v pljučih/hemoptizo.
• feeling of numbness or tingling in hands or feet, 
• občutek otrplosti ali zbadanja v dlaneh ali nogah,
MVASI infusions should not be administered or mixed with glucose solutions. 
Infuzije zdravila MVASI se ne sme dajati ali mešati skupaj z raztopinami glukoze.
The pharmacokinetic results show that the clearance and volume of distribution of bevacizumab were comparable between paediatric and adult patients when normalised by body weight, with exposure trending lower as body weight decreased. 
Farmakokinetični rezultati kažejo, da sta bila po normiranju glede na telesno maso očistek in volumen porazdelitve bevacizumaba med pediatričnimi in odraslimi bolniki primerljiva, z izpostavljenostjo, ki se je z manjšanjem telesne mase zmanjševala.
• It is possible that MVASI can increase the risk of bleeding in your lungs, including coughing or spitting blood. 
• možno je, da lahko zdravilo MVASI poveča tveganje za krvavitve v pljučih, vključno s kašljanjem in izpljuvanjem krvi.
0.80 (p = 0.003) 95% CI (0.69; 0.93) 
0,80 (p = 0,003) 95-% interval zaupanja (0,69; 0,93)
MVASI is administered in combination with one of the following chemotherapy regimens: paclitaxel and cisplatin or paclitaxel and topotecan. 
Zdravilo MVASI se uporablja v kombinaciji z eno od naslednjih shem kemoterapije: paklitaksel in cisplatin ali paklitaksel in topotekan.
Each pack of MVASI contains one vial. 
Vsako pakiranje zdravila MVASI vsebuje 1 vialo.
MVASI is a biosimilar medicinal product. 
Zdravilo MVASI je podobno biološko zdravilo.
• dry mouth in combination with thirst and/or reduced or darkened urine, 
• suha usta v kombinaciji z žejo in/ali manjšim izločanjem seča ali temnejši seč,
Clinical safety data suggest that the incidence of hypertension is likely to be dose-dependent. 
Podatki o klinični varnosti kažejo, da je incidenca hipertenzije najverjetneje odvisna od odmerka zdravila.
The majority of the patients in each treatment arm (74% and 71%) had poorly differentiated (grade 3) 
Večina bolnic v vsaki skupini (74 % in 71 %) je imela pred začetkom zdravljenja slabo diferenciran (stopnje 3) primarni tumor.
METHOD AND ROUTE(S) OF ADMINISTRATION For intravenous use after dilution. 
POSTOPEK IN POT(I) UPORABE ZDRAVILA Za intravensko uporabo po razredčitvi.
• if you develop severe high blood pressure requiring treatment with blood pressure medicines, 
• če se pojavi zelo visok krvni tlak, ki ga je treba zdraviti z zdravili proti zvišanemu krvnemu tlaku,
MVASI has been developed and made to treat cancer by injecting it into the bloodstream. 
Zdravilo MVASI so razvili in izdelali za zdravljenje raka in injiciranje v krvni obtok.
FOLFOX-4 or XELOX + placebo (n = 701) 
FOLFOX-4 ali XELOX + placebo (n = 701)
• symptoms that suggest changes in normal brain function (headaches, vision changes, confusion, or seizures), and high blood pressure, 
• simptomi, ki nakazujejo spremembe v normalnem delovanju možganov (glavoboli, spremembe vida, zmedenost ali epileptični napadi) in visok krvni tlak,
The addition of erlotinib to bevacizumab did not result in an improvement in OS (HR = 1.764; p = 0.1789), duration of objective response (6.7 vs. 9.1 months) or time to symptom progression (HR = 1.172; p = 0.5076). 
Dodatek erlotiniba bevacizumabu ni prispeval k izboljšanju celokupnega preživetja (HR = 1,764; p = 0,1789), trajanja objektivnega odgovora na zdravljenje (6,7 v primerjavi z 9,1 meseca) ali časa do napredovanja simptomov (HR = 1,172; p = 0,5076).
MVASI must be administered under the supervision of a physician experienced in the use of antineoplastic medicinal products. 
Zdravilo MVASI je treba dajati pod nadzorom zdravnika z izkušnjami pri uporabi zdravil za zdravljenje novotvorb.
Most patients in both the CP arm (80.4%) and the CPB arm (78.9%) were white. 
Večina bolnic tako v skupini CP (80,4 %) kot v skupini CPB (78,9 %) je bila belk.
Post-marketing adverse reactions are included in both tables 1 and 2, where applicable. 
Neželeni učinki, opisani po prihodu zdravila na trg, so vključeni v preglednico 1 in 2, kjer je ustrezno.
In situations where early discontinuation of chemotherapy was required, treatment with bevacizumab as a single agent continued until disease progression. 
V primerih, kjer je bila potrebna zgodnja ukinitev kemoterapije, so do napredovanja bolezni zdravljenje nadaljevali le z bevacizumabom.
• an enlargement and weakening of a blood vessel wall or a tear in a blood vessel wall (aneurysms and artery dissections). 
• razširitev in oslabitev stene krvne žile ali raztrganina v steni krvne žile (anevrizme in disekcije arterij).
Efficacy results for trials AVF0780g and AVF2192g 
Rezultati učinkovitosti iz preskušanj AVF0780g in AVF2192g AVF0780g
Most patients were FIGO stage III (both 68%) followed by FIGO stage IV (13% and 14%), FIGO stage II (10% and 11%) and FIGO stage I (9% and 7%). 
Večina bolnic je imela po FIGO klasifikaciji bolezen stadija III (v obeh skupinah 68 %), sledile so bolnice s stadijem IV po FIGO klasifikaciji (13 % in 14 %), stadijem II po FIGO klasifikaciji (10 % in 11 %) in stadijem I po FIGO klasifikaciji (9 % in 7 %).
If you have headache, vision changes, confusion or seizure with or without high blood pressure, please contact your doctor. 
Če imate glavobol, spremembe vida, ste zmedeni ali imate epileptični napad z visokim krvnim pritiskom ali brez njega, obvestite svojega zdravnika.
• problems with wound healing after surgery, 
• težave s celjenjem ran po operaciji,
MVASI should be prepared by a healthcare professional using aseptic technique to ensure the sterility of the prepared solution. 
Zdravilo MVASI mora pripraviti zdravstveno osebje v aseptičnih pogojih, da zagotovi sterilnost pripravljene raztopine.
Assessment of bevacizumab metabolism in rabbits following a single IV dose of 125I-bevacizumab indicated that its metabolic profile was similar to that expected for a native IgG molecule which does not bind VEGF. 
Ocena presnove pri kuncih po enkratnem intravenskem odmerku 125I-bevacizumaba je pokazala, da ima bevacizumab podoben presnovni profil kot pričakovani za nativne molekule IgG, ki se ne vežejo na VEGF.
No incompatibilities between MVASI and polyvinyl chloride or polyolefin bags or infusion sets have been observed. 
Med zdravilom MVASI in polivinil kloridom ali poliolefinskimi vrečkami ali infuzijskimi seti ni bilo inkompatibilnosti.
In this trial, there were two primary objectives: to show that XELOX was non-inferior to FOLFOX-4 and to show that bevacizumab in combination with FOLFOX-4 or XELOX chemotherapy was superior to chemotherapy alone. 
V tem preskušanju sta bila primarna cilja dva: pokazati, da je shema XELOX neinferiorna shemi FOLFOX-4, in da je bevacizumab v kombinaciji s kemoterapevtskima shemama FOLFOX-4 ali XELOX superiorno samostojni kemoterapiji.
• MVASI may increase the risk of developing serious infections of the skin or deeper layers under the skin, especially if you had holes in the gut wall or problems with wound healing. 
• zdravilo MVASI lahko poveča tveganje za nastanek resnih okužb kože ali globljih plasti pod kožo, še posebej, če se vam je stena črevesja preluknjala ali ste imeli težave pri celjenju ran.
Across clinical trials, the following grade 3 and 4 (NCI-CTCAE v.3) laboratory abnormalities occurred in patients treated with bevacizumab with at least a 2% difference compared to the corresponding control groups: hyperglycaemia, decreased haemoglobin, hypokalaemia, hyponatraemia, decreased white blood cell count, increased international normalised ratio (INR). 
Naslednje laboratorijske nepravilnosti stopnje 3 in 4 (NCI-CTCAE v.3) so se v kliničnih preskušanjih pri bolnikih, ki so se zdravili z bevacizumabom, v primerjavi z ustreznimi kontrolnimi skupinami pojavile z najmanj 2-% razliko: hiperglikemija, zmanjšana koncentracija hemoglobina, hipokaliemija, hiponatriemija, zmanjšano število belih krvnih celic, zvečano internacionalno normalizirano razmerje.
Immune system disorders Hypersensitivity reactions and infusion reactions (not known); with the following possible co-manifestations: dyspnoea/difficulty breathing, flushing/redness/rash, hypotension or hypertension, oxygen desaturation, chest pain, rigors and nausea/vomiting (see also section 4.4 and Hypersensitivity reactions/infusion reactions above) 
Bolezni imunskega sistema preobčutljivostne reakcije ter reakcije pri infundiranju (ni znana); z naslednjimi možnimi znaki: dispneja/težave pri dihanju, pordevanje/rdečina/izpuščaj, hipotenzija ali hipertenzija, zmanjšana saturacija s kisikom, bolečina v prsnem košu, okorelost ter navzea/bruhanje (glejte tudi poglavje 4.4 ter podnaslov Preobčutljivostne reakcije/reakcije pri infundiranju, zgoraj)
Very rare Frequency not known 
Neznana pogostnost
Proteinuria ranged in severity from clinically asymptomatic, transient, trace proteinuria to nephrotic syndrome, with the great majority as grade 1 proteinuria (NCI-CTCAE v.3). 
Proteinurija je po resnosti obsegala od klinično asimptomatske, prehodne, proteinurije v sledovih vse do nefrotskega sindroma, večinoma pa je bila proteinurija stopnje 1 (NCI-CTCAE v.3).
The clinical benefit, as measured by overall survival, was seen in all prespecified patient subgroups, including those defined by age, sex, performance status, location of primary tumour, number of organs involved and duration of metastatic disease. 
Klinična korist, katere merilo je bilo celokupno preživetje, se je pokazala pri vseh že prej izbranih podskupinah, vključno s podskupinami, osnovanimi glede na starost, spol, splošno stanje zmogljivosti, lokalizacijo primarnega tumorja, število prizadetih organov in trajanje metastatske bolezni.
• a hole in the cartilage wall separating the nostrils of the nose, 
• predrtje nosnega pretina (stena iz hrustanca, ki ločuje nosnici),
During the trial, of the patients who received trial treatment, 32.2% (136/422) of patients received 7-12 administrations of bevacizumab and 21.1% (89/422) of patients received 13 or more administrations of bevacizumab. 
Med preskušanjem je od bolnikov, ki so prejemali zdravilo v preskušanju, 32,2 % bolnikov (136/422) prejelo 7 do 12 odmerkov bevacizumaba, 21,1 % (89/422) bolnikov pa je prejelo 13 ali več odmerkov bevacizumaba.